Tamoxifen in the treatment of male breast carcinoma.
dc.contributor.author | Ribeiro, G | |
dc.date.accessioned | 2014-12-22T15:45:48Z | |
dc.date.available | 2014-12-22T15:45:48Z | |
dc.date.issued | 1983-11 | |
dc.identifier.citation | Tamoxifen in the treatment of male breast carcinoma. 1983, 34 (6):625-8 Clin Radiol | en |
dc.identifier.issn | 0009-9260 | |
dc.identifier.pmid | 6673881 | |
dc.identifier.uri | http://hdl.handle.net/10541/337550 | |
dc.description.abstract | Twenty-four patients with advanced carcinoma of the male breast have been treated with tamoxifen citrate (Nolvadex). An objective regression rate of 37.5% was obtained, with five complete and four partial responses. In addition, two patients had stabilisation of their disease for 24 months each. Regression of disease was noted in soft-tissue disease, bone and lung metastases. The duration of response ranged from 8 months to 60 months with a mean of 21 months. In view of the singular lack of side-effects and the age group of the patients (mean age 63 years), it is suggested that tamoxifen should be the first line of endocrine therapy before orchidectomy or adrenalectomy. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Clinical radiology | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Breast Neoplasms | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Metastasis | |
dc.subject.mesh | Receptors, Estrogen | |
dc.subject.mesh | Receptors, Progesterone | |
dc.subject.mesh | Tamoxifen | |
dc.title | Tamoxifen in the treatment of male breast carcinoma. | en |
dc.type | Article | en |
dc.contributor.department | Department of Radiotherapy, The Christie Hospital & Holt Radium Institute, Manchester | en |
dc.identifier.journal | Clinical Radiology | en |
html.description.abstract | Twenty-four patients with advanced carcinoma of the male breast have been treated with tamoxifen citrate (Nolvadex). An objective regression rate of 37.5% was obtained, with five complete and four partial responses. In addition, two patients had stabilisation of their disease for 24 months each. Regression of disease was noted in soft-tissue disease, bone and lung metastases. The duration of response ranged from 8 months to 60 months with a mean of 21 months. In view of the singular lack of side-effects and the age group of the patients (mean age 63 years), it is suggested that tamoxifen should be the first line of endocrine therapy before orchidectomy or adrenalectomy. |